Guggenheim Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $9
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces a price target of $9.
June 12, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim initiates coverage on Centessa Pharmaceuticals with a Buy rating and a price target of $9.
Guggenheim's initiation of coverage on Centessa Pharmaceuticals with a Buy rating and a price target of $9 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100